OR WAIT null SECS
Kevin E. Noonan, PhD, noonan@mbhb.com, is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s Biotechnology & Pharmaceuticals Practice Group.
November 06, 2020
Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.